Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2007

View Archived Issues

New data provided by EAE models for multiple sclerosis

New clinical trial results for rotigotine in Parkinson's disease, restless legs syndrome

Antitumor activity of novel PI3K inhibitor reported by Zentaris

Novel CDK inhibitor SCH-727965 shows broad antitumor activity in preclinical studies

New therapeutic agents for benign prostatic hyperplasia disclosed in recent Ranbaxy patent

Recent data suggest that lacosamide has low potential for drug-drug interaction

Novel antiinfective agents disclosed in recent patent literature

Novel agents for cardiovascular disorders disclosed in recent Taisho and Boehringer patents

Biosite and Beckman Coulter amend merger agreement

Phase Ib study to begin for optimized TPM-02/Insulin

Cardiome Pharma in-licenses GED-aPC

Rituximab beneficial in myositis, polyneuropathy, neuromyelitis optica

Laquinimod reduces disease activity in relapsing-remitting MS

Phase III trial finds Imagify non-inferior to nuclear stress

Positive phase I findings for DG-051 for prevention of heart attack

Schering-Plough reviews Q1

TH-302 demonstrates activity in orthotopic models of cancer

Pro-Pharmaceuticals and Digna collaborate in hepatitis C

ViroPharma to establish European subsidiary for maribavir

Ark seeks clearance for phase III study of Trinam

ThromboGenics reviews preclinical pipelines progression

Target enrollment reached in phase IIb study of ozarelix for BPH

Cadence plans to increase patient numbers in phase III Omnigard trial

Enrollment under way in phase II study of FTY-720 for relapsing-remitting MS

Belinostat studied with doxorubicin in new phase I/II trial for soft tissue sarcomas

Enzon cleared to begin phase I study of PEG-SN38 in cancer

Tbeta4 cleared for phase II study in diabetics undergoing vitrectomy surgery

Herceptin approved for new breast cancer indication in E.U.

Supprelin-LA approved for central precocious puberty

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...